|
| Author | Year | Included patients () | Genotype 1 (%) | FCH | PEG-INF alpha (dose) | RBV dose (mg/day) | Time since LT | Treatment duration (months) | Growth factor | SVR,
(%) | Discontinuation (%) | Dose reductions (%) |
|
| Rodriguez-Luna et al. [199] | 2004 | 19 | 63 | NA | 2b: 0.5–1.5 μg/kg per week () | 400 then escalated to 800–1000 | 4.2 (1–16.2) | 12 | Yes | 5 (26) | 7 (38) | NA |
| Neff et al. [200] | 2004 | 57 | 98 | NA | 2b: 1.5 μg/kg per week () | 400–600 | 23.5 (1.6–84.7) | 12 | Yes | 8 (14) | 18 (32) | INF 38 (67), RBV 22 (39) |
| Ross et al. [201] | 2004 | 16 | 69 | 2 | 2b: 1.5 μg/kg per week () | 800–1200 | 9.5 | 12 | Yes | 0 (0) | 8 (50) | INF 12 (75), RBV 13 (81) |
| Dumortier et al. [202] | 2004 | 20 | 80 | 0 | 2b: 0.5–1 μg/kg per week () | 400 | 28 (3–103) | 12 | No | 9 (45) | 4 (20) | INF 13 (65), RBV 6 (30) |
| Babatin et al. [203] | 2005 | 13 | 46 | 0 | 2b: 0.9 μg/kg per week () | 600 | 24 (6–73) | 12 | Yes | 4 (31) | 7 (54) | 9 (72) |
| Toniutto et al. [204] | 2005 | 12 | 100 | 0 | 2b: 0.5 μg/kg per week () | 600–800 | 14 (0.6–60.8) | 12 | No | 1 (8) | 7 (58) | 11 (92) |
| Castells et al. [205] | 2005 | 24 | 10 | 0 | 2b: 1.5 μg/kg per week () | 600 | 3.8 ± 2.2 | 12 | Yes | 8 (35) | 3 (13) | INF 6 (25), RBV 14 (58) |
| Biselli et al. [206] | 2006 | 20 | 80 | 0 | 2b: 1 μg/kg per week () | 600 | 56.5 (13–157) | 12 | Yes | 9 (45) | 1 (5) | RBV 7 (35) |
| Berenguer et al. [207] | 2006 | 36 | 89 | NA | 2b: 1.5 μg/kg per week (),
2a: 180 μg/week () | 600–1200 | 16.6 (2.7–132.6) | 12 | Yes | 18 (50) | 17 (47) | 19 (53) |
| Oton et al. [208] | 2006 | 55 | 91 | 0 | 2b: 1.5 μg/kg per week (),
2a: 180 μg/week () | 800–1200 | 63.3 ± 45.5 | G1/4: 12, G2/3: 6 | Yes | 24 (44) | 16 (29) | INF 17 (31), RBV 17 (31) |
|
Mukherjee and Lyden [209] | 2006 | 32 | 75 | NA | 2a: 180 μg/week () | 800 then escalated to 1000–1200 | 16 (2–70) | G1/4: 12, G2/3: 6 | Yes | 11 (34) | 5 (16) | NA |
|
Mukherjee and Lyden [210] | 2006 | 39 | 79 | NA | 2b: 1.5 μg/kg per week () | 800 | 20 (2–168) | G1/4: 12, G2/3: 6 | No | 13 (33) | 17 (44) | NA |
| Fernández et al. [211] | 2006 | 47 | 94 | 10 | 2b: 1.5 μg/kg per week () | 600–800 | 32 ± 25 | 12 | Yes | 11 (23) | 10 (21) | RBV 15 (32) |
| Neumann et al. [212] | 2006 | 25 | 80 | 0 | 2b: 1 μg/kg per week () | 600 | 38 (2–108) | 12 | Yes | 9 (36) | 1 (4) | INF 15 (52), RBV 9 (36) |
| Neumann et al. [212] |
2006 | 61 | 87 | 0 | 2b: 1 μg/kg per week () | 600–800 | 25 (3–131) | G1/4: 12, G2/3: 6 | No | 17 (28) | 9 (15) | 48 (79) |
| Angelico et al. [214] | 2007 | 42 | 81 | 0 | 2a: 180 μg/week () | 200 then escalated to 1200 until tolerated | 48 ± 29 | 12 | No | 7 (33) | 7 (33) | INF 8 (38), RBV 21 (100) |
| Carrión et al. [215] | 2007 | 81 | 93 | 4 | 2b: 1.5 μg/kg per week () | 400–1200 adjusted for renal function | 14.5 (2–38) | 12 | Yes | 18 (33) | 21 (39) | INF 13 (24), RBV 36 (67) |
| Sharma et al. [216] | 2007 | 35 | 77 | 1 | 2b: 1.5 μg/kg per week,
2a: 180 μg/week, (no of patients not stated) | 800 | 16 (1.5–129) | 12 | Yes | 13 (37) | 15 (43) | NA |
| Zimmermann et al. [217] | 2007 | 26 | 88 | 0 | 2a: 90 μg/week for 4 weeks then escalated to 135–180 μg/week () | 600 then escalated to 800–1200 | 9.4 ± 3.6 | 12 | Yes | 5 (19) | 3 (12) | 17 (65) |
| Dinges et al. [218] |
2009 | 19 | 68 | NA | 2a: 180 μg/week () | 10 mg/kg/day | 23 (6–162) | 12 | Yes | 9 (47) | 5 (26) | INF 8 (50), RBV 7 (37) |
| Lodato et al. [219] | 2008 | 53 | 100 | 0 | 2b: 1.0 μg/kg per week () | 8–10 mg/kg/day | 14 (3–151) | 12 | Yes | 14 (26) | 24 (45) | INF 3 (6), RBV 21 (40) |
| Roche et al. [27] | 2008 | 133 (29: INF) | 75 | NA | 2b: 0.6–1.5 μg/kg per week (), 2a: 90–180 μg/week () | 1.8–16.9 mg/kg/day | 86 (5–231) | 12 | Yes | 58 (44) | 41 (38) | INF 41 (38), RBV 80 (60) |
| Hanouneh et al. [220] | 2008 | 53 | 79 | 0 | 2b: 1.5 μg/kg per week,
2a: 180 μg/week, (no. of patients not stated) | 1000–1200 | 15 (7–39) | 12 | Yes | 19 (35) | 14 (26) | 31 (58) |
| Berenguer et al. [28] | 2009 | 107 | 86 | 11 | 2b: 1.5 μg/kg per week (),
2a: 180 μg/week () | 600–1200 | 21 (2–133) | 12 | Yes | 39 (37) | | INF 37 (35), RBV 43 (40) |
| Selzner et al. [26] | 2009 | 172 (36: INF) | 68 | 6 | 2b: 1.5 μg/kg per week,
2a: 180 μg/week, (no. of patients not stated) | 800–1000 | 19 (1–149) | 12 | Yes | 86 (50) | 29 (17) | 80 (47%) |
| Schmidt et al. [221] | 2010 | 83 | 88 | NA | 2b: 1.0 μg/kg per week (),
2a: 180 μg/week () | 400–1000 | 41 (0.6–144) | 12 | Yes | 31 (26) | 24 (29) | 49 (51) |
| Jain et al. [222] | 2010 | 60 | 93 | NA | 2b: 1–1.5 μg/kg per week (),
2a: 180 μg/week () | 800 | 29 ± 28 | 12 | Yes | 21 (35) | 24 (40) | INF 21 (35), RBV 16 (27) |
| Al-Hamoudi et al. [223] | 2011 | 25 | 0 (All genotype 4) | NA | 2a: 180 μg/week () | 400–1200 | 14 (1–72) | 12 | Yes | 14 (56) | 1 (4) | INF 0 (0), RBV 7 (28) |
|
